1
2

To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.

2/26/2026, 9:06 AM

Summary of Bill HR 7693

H.R. 7693, introduced in the 119th Congress on February 25, 2026, aims to mitigate the impact of the COVID-19 pandemic on incentives related to orphan drug development under the Federal Food, Drug, and Cosmetic Act.

Current Status of Bill HR 7693

Bill HR 7693 is currently in the status of Bill Introduced since February 25, 2026. Bill HR 7693 was introduced during Congress 119 and was introduced to the House on February 25, 2026.  Bill HR 7693's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 25, 2026

Bipartisan Support of Bill HR 7693

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 7693

Primary Policy Focus

Alternate Title(s) of Bill HR 7693

To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.
To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.

Comments